de Sain-van der Velden M G, Kaysen G A, Barrett H A, Stellaard F, Gadellaa M M, Voorbij H A, Reijngoud D J, Rabelink T J
Department of Nephrology, University Hospital Utrecht, The Netherlands.
Kidney Int. 1998 Apr;53(4):994-1001. doi: 10.1111/j.1523-1755.1998.00831.x.
Increased very low density lipoprotein (VLDL) in nephrotic patients results from a decreased catabolism while increased low density lipoprotein (LDL) results from increased synthesis. Hyperlipidemia is a hallmark of nephrotic syndrome that has been associated with increased risk for ischemic heart disease as well as a loss of renal function in these patients. The hyperlipidemia usually is characterized by increased cholesterol levels, although hypertriglyceridemia may be present as well. The factors that determine the phenotype of nephrotic dyslipidemia are not understood, nor has the primary stimulus for nephrotic hyperlipidemia been identified. One hypothesis is that nephrotic hyperlipidemia is the result of a coordinate increase in synthesis of proteins by the liver. To address these issues we simultaneously measured the in vivo rate of VLDL apolipoprotein B100 (apo B100) secretion, LDL apo B100 synthesis and albumin synthesis in patients with a nephrotic syndrome (N = 8) and compared them with a control group (N = 7) using a primed/continuous infusion of the stable isotope L-[1-13C] valine for six hours. Kinetic data were analyzed by multicompartmental analysis. Patients studied had combined hyperlipidemia as reflected by an significant increase in both VLDL and LDL apo B100 pool sizes. In contrast, the albumin pool size was significantly decreased. VLDL apo B100 levels were primarily increased as a consequence of a decrease in fractional catabolic rate (FCR) rather than from an increase in the absolute synthesis rate (ASR). Both VLDL apo B100 and triglycerides were inversely related to the fractional catabolism (FCR) of VLDL apo B100 (r2 = 0.708; P = 0.0088) while neither had any relationship to the ASR of VLDL apo B100. In contrast to VLDL, increased LDL apo B100 was not a consequence of decreased catabolism. The LDL apo B100 ASR was significantly increased (P = 0.001) in the nephrotic patients compared to controls. Low density lipoprotein apo B100 ASR was greater than that of VLDL apo B100 in some patients, suggesting that LDL in these patients was not only derived from VLDL delipidation, but also by an alternative secretory pathway. There was no clear relationship between the ASR of VLDL apo B100 and the ASR of albumin within the current study population. Our data indicate that increased VLDL in nephrotic patients results from a decreased catabolism, while increased LDL results from increased synthesis.
肾病患者极低密度脂蛋白(VLDL)增加是由于分解代谢减少,而低密度脂蛋白(LDL)增加则是由于合成增加。高脂血症是肾病综合征的一个标志,与这些患者缺血性心脏病风险增加以及肾功能丧失有关。高脂血症通常以胆固醇水平升高为特征,不过也可能存在高甘油三酯血症。决定肾病性血脂异常表型的因素尚不清楚,肾病性高脂血症的主要刺激因素也未被确定。一种假说认为,肾病性高脂血症是肝脏蛋白质合成协同增加的结果。为了解决这些问题,我们使用稳定同位素L-[1-13C]缬氨酸进行6小时的预充/持续输注,同时测量了肾病综合征患者(N = 8)体内VLDL载脂蛋白B100(apo B100)的分泌率、LDL apo B100的合成率和白蛋白的合成率,并将其与对照组(N = 7)进行比较。通过多室分析对动力学数据进行分析。所研究的患者存在混合性高脂血症,表现为VLDL和LDL apo B100池大小均显著增加。相比之下,白蛋白池大小显著降低。VLDL apo B100水平主要因分解代谢率分数(FCR)降低而升高,而非绝对合成率(ASR)增加。VLDL apo B100和甘油三酯均与VLDL apo B100的分解代谢率分数(FCR)呈负相关(r2 = 0.708;P = 0.0088),而两者与VLDL apo B100的ASR均无关系。与VLDL不同,LDL apo B100增加并非分解代谢减少的结果。与对照组相比,肾病患者的LDL apo B100 ASR显著增加(P = 0.001)。在一些患者中,低密度脂蛋白apo B100的ASR大于VLDL apo B100的ASR,这表明这些患者的LDL不仅来源于VLDL的脱脂,还通过另一种分泌途径产生。在当前研究人群中,VLDL apo B100的ASR与白蛋白的ASR之间没有明确的关系。我们的数据表明,肾病患者VLDL增加是由于分解代谢减少,而LDL增加是由于合成增加。